Dear All,
Today, we announced top-line results from our Phase 2 study of nezulcitinib in patients hospitalized with acute lung injury due to COVID-19. Read our press release here.
In response to the global pandemic last year, we, like many others in the healthcare industry, were moved to act. Given our heritage in developing respiratory therapies, we looked directly at our current pipeline and decided to accelerate nezulcitinib (also known as TD-0903 at the time), our investigational, lung-selective, inhaled pan-JAK inhibitor, from pre-clinical stage into the clinic.
This data announcement is the culmination of almost fifteen months of expedited drug development. In that time, our team has completed a Phase 1 trial in healthy volunteers, and an initial dose-selection portion of the Phase 2, culminating with this randomized, double-blind placebo-controlled, multi-center study in 200-plus patients with severe COVID-19.
Even though the study didn’t meet the primary endpoint, we are encouraged by what we did see in the data:
To learn more about the data, view our top-line presentation on our website (here).
These data demonstrate that nezulcitinib, on top of standard of care and in a specific patient population, has the potential to help preserve lung function, which may allow patients to recover faster and reduce deaths
We are grateful to the patients and their families, our research partners, the clinical investigators, and our internal team at Theravance Biopharma for their important contributions to this study.
Rick E Winningham, CEO
Theravance Biopharma aims to transform the treatment of serious diseases through the discovery and development of organ-selective medicines designed to maximize patient benefit while minimizing patient risk.
Our research is focused in the areas of inflammation and immunology, and our pipeline of internally discovered programs is targeted to address significant patient needs.
Theravance Biopharma is a place for collaborators and creative problem-solvers – people who thrive on applying insight and innovation to discovering novel medicines.
Learn how our dedication to patients expands beyond the laboratory.
Our integrated team is committed to developing and providing the world with organ-selective medicines for serious diseases.
We leverage insight and innovation to transform the treatment of serious diseases.
